Results 21 to 30 of about 16,388 (147)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

open access: yesJACC: Advances
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a)
Frederick Berro Rivera, MD   +10 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control

open access: yesEuropean Cardiology Review, 2023
The breakthrough discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) 20 years ago revolutionised the current understanding of cholesterol homeostasis. Genetic studies have shown that gain-of-function mutations in PCSK9 lead to elevated LDL
Rishi Rikhi, Michael D Shapiro
doaj   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

open access: yesiNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little   +12 more
wiley   +1 more source

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

open access: yesTzu Chi Medical Journal
A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases.
Je-Wen Liou   +3 more
doaj   +1 more source

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction

open access: yesРоссийский кардиологический журнал, 2020
Aim. To study the levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with acute myocardial infarction (MI).Material and methods. The study included 74 patients with acute MI.
A. D. Gimadeeva   +3 more
doaj   +1 more source

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency

open access: yesObesity, EarlyView.
ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak   +2 more
wiley   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

open access: yesPediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil   +2 more
wiley   +1 more source

Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea

open access: yesTürk Biyokimya Dergisi
We aimed to investigate the relationship among proprotein convertase subtilisin/kexin type 9 (PCSK9), adropin levels, inflammation, and sleep variables in non-diabetic males with severe obstructive sleep apnea (OSA).
Deniz Levent   +4 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

open access: yesFrontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu   +3 more
doaj   +1 more source

Whole‐transcriptome sequencing analyses identified exosomal circular RNAs in the plasma of pancreatic cancer patients as novel blood‐based biomarkers of disease

open access: yesVIEW, EarlyView.
Pancreatic cancer (PaCa) has a poor prognosis, with low resection rates and high relapse rates, highlighting the urgent need for novel diagnostic biomarkers. Here, we performed whole‐transcriptome sequencing of plasma‐derived exosomes from PaCa patients and identified several differentially expressed circular RNAs (circRNAs).
Xiaomeng He   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy